U.S. markets open in 3 hours 13 minutes
  • S&P Futures

    3,655.75
    -4.75 (-0.13%)
     
  • Dow Futures

    29,723.00
    -81.00 (-0.27%)
     
  • Nasdaq Futures

    12,441.75
    -10.50 (-0.08%)
     
  • Russell 2000 Futures

    1,830.80
    -4.70 (-0.26%)
     
  • Crude Oil

    44.53
    -0.02 (-0.04%)
     
  • Gold

    1,832.10
    +13.20 (+0.73%)
     
  • Silver

    24.31
    +0.22 (+0.89%)
     
  • EUR/USD

    1.2054
    -0.0025 (-0.20%)
     
  • 10-Yr Bond

    0.9340
    0.0000 (0.00%)
     
  • Vix

    20.84
    +0.27 (+1.31%)
     
  • GBP/USD

    1.3357
    -0.0066 (-0.49%)
     
  • USD/JPY

    104.6880
    +0.3720 (+0.36%)
     
  • BTC-USD

    19,070.77
    -100.97 (-0.53%)
     
  • CMC Crypto 200

    374.20
    -5.66 (-1.49%)
     
  • FTSE 100

    6,398.63
    +13.90 (+0.22%)
     
  • Nikkei 225

    26,800.98
    +13.44 (+0.05%)
     

Osteoporosis drug helps Amgen third-quarter profit beat estimates

Deena Beasley
·2 min read

By Deena Beasley

Oct 28 (Reuters) - Amgen Inc on Wednesday said its third-quarter adjusted profit rose 17% due to stronger sales of drugs including the osteoporosis treatment Prolia and recently-acquired psoriasis medication Otezla.

The higher-than-expected results were partially offset by lower drug prices and the effects of the COVID-19 pandemic.

The biotechnology company said that more patients had resumed interacting with their doctors in the third quarter than earlier in the health crisis, but prescribing volumes remained "modestly below" pre-pandemic levels.

The company raised its full-year adjusted earnings forecast to $15.80 to $16.15 per share, from a previous range of $15.10 to $15.75, and narrowed its revenue estimate. It now expects revenue of $25.1 billion to $25.5 billion versus it prior forecast of $25.0 billion to $25.6 billion.

Amgen also lowered its expected 2020 tax rate to 13% to 14% from 13.5% to 14.5%.

The company reported a third-quarter adjusted profit $4.37 per share, beating the average estimate of $3.81 per share, as compiled by Refinitiv.

Revenue for the quarter rose 12% to $6.4 billion, in line with analyst estimates of $6.38 billion.

Sales of Prolia rose 11% to $701 million, ahead of the average analyst estimate of $688 million.

Psoriasis drug Otezla, acquired from Celgene Corp in November, had sales of $538 million for the quarter, falling short of analyst expectations of $587 million.

Sales of Amgen's older arthritis drug Enbrel fell 3% year-over-year to $1.3 billion as the drug continued to lose market share in the quarter. That still topped analysts' expectations of $1.26 billion.

Amgen's posted a net income of $2.02 billion, or $3.43 per share, compared with a profit of $1.97 billion, or $3.27 a share, a year ago. (Reporting By Deena Beasley Editing by Bill Berkrot)